[go: up one dir, main page]

DK1169063T3 - Behandling af intracellulære infektioner - Google Patents

Behandling af intracellulære infektioner

Info

Publication number
DK1169063T3
DK1169063T3 DK00919042T DK00919042T DK1169063T3 DK 1169063 T3 DK1169063 T3 DK 1169063T3 DK 00919042 T DK00919042 T DK 00919042T DK 00919042 T DK00919042 T DK 00919042T DK 1169063 T3 DK1169063 T3 DK 1169063T3
Authority
DK
Denmark
Prior art keywords
agent
target cell
phage
treatment
intracellular infections
Prior art date
Application number
DK00919042T
Other languages
English (en)
Inventor
Vladimir Artymovich Pasechnik
Allen Douglas Glen Roberts
Richard James Sharp
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of DK1169063T3 publication Critical patent/DK1169063T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK00919042T 1999-04-09 2000-04-10 Behandling af intracellulære infektioner DK1169063T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9908195.2A GB9908195D0 (en) 1999-04-09 1999-04-09 Treatment of intracellular infection
PCT/GB2000/001350 WO2000061190A2 (en) 1999-04-09 2000-04-10 Treatment of intracellular infection
EP00919042A EP1169063B1 (en) 1999-04-09 2000-04-10 Treatment of intracellular infection

Publications (1)

Publication Number Publication Date
DK1169063T3 true DK1169063T3 (da) 2004-11-01

Family

ID=10851274

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00919042T DK1169063T3 (da) 1999-04-09 2000-04-10 Behandling af intracellulære infektioner

Country Status (12)

Country Link
US (1) US6660264B1 (da)
EP (1) EP1169063B1 (da)
JP (1) JP2002541217A (da)
AT (1) ATE270115T1 (da)
AU (1) AU772115B2 (da)
CA (1) CA2372078A1 (da)
DE (1) DE60011880T2 (da)
DK (1) DK1169063T3 (da)
ES (1) ES2220451T3 (da)
GB (1) GB9908195D0 (da)
PT (1) PT1169063E (da)
WO (1) WO2000061190A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221713A1 (en) * 2000-10-25 2002-05-06 Intercell Biomedizinische Forschulungs- Und Entwicklungs Ag Modified phage, comprising a non-lytic modification and expressing a kil-gene
JP2004537515A (ja) 2001-05-15 2004-12-16 フォーク ファーマシューティカルス，インク． ウィルス感染症治療用薬物のターゲッティング送達
GB0115385D0 (en) * 2001-06-22 2001-08-15 Regma Biotechnologies Ltd Novel preparation
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
WO2003066003A2 (en) * 2002-02-07 2003-08-14 Massachusetts Institute Of Technology Anti-pathogen treatements
GB0205786D0 (en) * 2002-03-12 2002-04-24 Regma Bio Technologies Ltd Novel Composition
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
DE10235967B4 (de) * 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
WO2004087924A2 (en) * 2003-03-31 2004-10-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for delivery of substances to intracellular microorganisms
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
JP2007523159A (ja) * 2004-02-20 2007-08-16 ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド Ｒｎａ干渉分子の標的送達
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
JP5307023B2 (ja) * 2006-12-12 2013-10-02 モルフォシス・アー・ゲー 内在化
US8619257B2 (en) * 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
EP3208282A1 (en) 2010-11-30 2017-08-23 F. Hoffmann-La Roche AG Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier
BR112022017797A2 (pt) * 2020-03-06 2022-11-29 Endolytix Tech Inc Métodos de distribuição de um bacteriófago, de tratamento de uma infecção bacteriana, de isolamento de um fago direcionado a uma bactéria e composição
WO2025018388A1 (ja) * 2023-07-20 2025-01-23 学校法人自治医科大学 抗菌カプシド、治療用組成物、殺菌剤、細菌除去方法、殺菌方法、動物治療方法、遺伝子導入方法、細菌機能追加方法、抗菌カプシドの製造方法、抗菌カプシドの標識方法、及び抗菌カプシドの細胞内送達方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829266A (en) 1957-03-20 1960-03-02 Biogena A method of manufacturing bacteriophages in solid dry form
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL93982A0 (en) 1989-04-03 1991-01-31 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
EP0532525B1 (de) 1990-05-18 1995-08-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue protein-polykation-konjugate
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1992006191A1 (en) 1990-09-28 1992-04-16 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
EP0553235A1 (en) 1990-10-01 1993-08-04 The University Of Connecticut Targeting viruses and cells for selective internalization by cells
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
DK0573603T3 (da) 1991-03-01 2003-10-20 Dyax Corp Inhibitorer af human neutrofil elastase og human cathepsin G
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
DE4115038A1 (de) 1991-05-08 1992-11-12 Genentech Inc Neue konjugate, bestehend aus einem glykoprotein und einer nukleinsaeure-bindenden substanz
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5922859A (en) 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
JPH08509613A (ja) 1993-04-27 1996-10-15 シンバイオテック・インコーポレイテッド 化学的に改変されたラムドイドバクテリオファージを用いる化合物の検出方法
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
CA2186962A1 (en) 1994-04-05 1995-10-12 Richard M. Carlton Antibacterial therapy with genotypically modified bacteriophage
MX9605941A (es) 1994-05-30 1997-12-31 Boehringer Ingelheim Int Procedimiento para introducir material extraño en celulas eucarioticas superiores.
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
GB9412844D0 (en) 1994-06-27 1994-08-17 Medical Res Council Improvements in or relating to therapeutic methods
US5736388A (en) 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
WO1997023608A1 (en) 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
SE506771C2 (sv) 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
US6121036A (en) 1996-04-15 2000-09-19 Ghanbari; Hossein A. Compositions containing bacteriophages and methods of using bacteriophages to treat infections
WO1998005344A1 (en) * 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
WO1999010485A1 (en) 1997-08-29 1999-03-04 Selective Genetics, Inc. Methods using phage display for selecting internalizing ligands for gene delivery
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
DE19909770A1 (de) * 1999-03-05 2000-09-07 Werner Lubitz Bakterienghosts als Träger- und Targetingvehikel

Also Published As

Publication number Publication date
ES2220451T3 (es) 2004-12-16
WO2000061190A3 (en) 2001-03-01
PT1169063E (pt) 2004-10-29
CA2372078A1 (en) 2000-10-19
DE60011880D1 (de) 2004-08-05
US6660264B1 (en) 2003-12-09
DE60011880T2 (de) 2005-08-25
AU3979800A (en) 2000-11-14
EP1169063B1 (en) 2004-06-30
EP1169063A2 (en) 2002-01-09
ATE270115T1 (de) 2004-07-15
JP2002541217A (ja) 2002-12-03
WO2000061190A2 (en) 2000-10-19
AU772115B2 (en) 2004-04-08
GB9908195D0 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
DK1169063T3 (da) Behandling af intracellulære infektioner
YU4602A (sh) Farmaceutske formulacije zaštićene od dejstva mikroorganizama
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
SE0300010D0 (sv) Novel Compounds
TR200003170T2 (tr) MRS inhibitörleri ve bakterisid olarak kullanılan quinolone'lar
CR9807A (es) Uso de derivados de azabiciclohexano
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
MXPA03005464A (es) Agentes antivirales.
SG156624A1 (en) Organo-gel formulations for therapeutic applications
NO20024891L (no) Farmasöytiske sammensetninger
WO2001092288A3 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
NZ510369A (en) Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
AU2002213421A1 (en) Condensed pyridoindole derivatives
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
SE0101932D0 (sv) Pharmaceutical combinations
DK1037650T3 (da) Præparater til behandling af Staphylococcus aureus-infektioner
NZ503897A (en) 3,6-hemiketals from the class of 9a-azalides
AU2002213419A1 (en) Condensed pyridoindole derivatives
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
WO2021178818A3 (en) Therapeutic agents and conjugates thereof
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
DE60005530D1 (de) Antiseptische zusammensetzungen